Home > A. Molecular pathology > E2F1

E2F1

Wednesday 21 April 2004

The cellular transcription factor E2F1 is part of an anti-tumor safeguard mechanism: it engages cell-death pathways either alone or in cooperation with p53 to protect organisms from the development of tumors.

E2F1 activates downstream factors, which in turn produce secondary changes in gene expression that trigger apoptosis.

Pathology

- somatic mutation of E2F1 in a critical DNA binding residue in well-differentiated papillary mesothelioma of the peritoneum. (#21955916#)

See also

- E2Fs

References

- First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Yu W, Chan-On W, Teo M, Ong CK, Cutcutache I, Allen GE, Wong B, Myint SS, Lim KH, Voorhoeve PM, Rozen S, Soo KC, Tan P, Teh BT. Genome Biol. 2011 Sep 28;12(9):R96. PMID: #21955916#

Reviews

- Stanelle J, Putzer BM. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med. 2006 Apr;12(4):177-85. PMID: #16530485#

- Korenjak M, Brehm A. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr Opin Genet Dev. 2005 Oct;15(5):520-7. PMID: #16081278#

- Blais A, Dynlacht BD. Hitting their targets: an emerging picture of E2F and cell cycle control. Curr Opin Genet Dev. 2004 Oct;14(5):527-32. PMID: #15380244#

- Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001 Apr;10(7):699-703. PMID: #11257102#

Portfolio